
    
      poorly controlled (HbA1c >7.5%) T2DM patients (18-75 years of age) on maximal/near maximal
      dose of sulfonylurea plus metformin who otherwise are healthy will be randomized to receive:

        1. exenatide weekly injection (2 mg/week)

        2. glargine insulin plus insulin aspart which will be titrated to maintain HbA1c <7.0%
    
  